- Home
- AIM vs CARV Comparison
AIM vs CARV Comparison
Compare AIM & CARV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- CARV
- Stock Information
- Founded
- AIM 1966
- CARV 1948
- Country
- AIM United States
- CARV United States
- Employees
- AIM N/A
- CARV N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- CARV Savings Institutions
- Sector
- AIM Health Care
- CARV Finance
- Exchange
- AIM Nasdaq
- CARV Nasdaq
- Market Cap
- AIM 9.8M
- CARV 8.8M
- IPO Year
- AIM N/A
- CARV 1994
- Fundamental
- Price
- AIM $0.14
- CARV $1.75
- Analyst Decision
- AIM Strong Buy
- CARV
- Analyst Count
- AIM 2
- CARV 0
- Target Price
- AIM $2.75
- CARV N/A
- AVG Volume (30 Days)
- AIM 1.5M
- CARV 6.7K
- Earning Date
- AIM 04-01-2025
- CARV 02-13-2025
- Dividend Yield
- AIM N/A
- CARV N/A
- EPS Growth
- AIM N/A
- CARV N/A
- EPS
- AIM N/A
- CARV N/A
- Revenue
- AIM $190,000.00
- CARV $24,056,000.00
- Revenue This Year
- AIM N/A
- CARV N/A
- Revenue Next Year
- AIM $1,693.10
- CARV N/A
- P/E Ratio
- AIM N/A
- CARV N/A
- Revenue Growth
- AIM N/A
- CARV N/A
- 52 Week Low
- AIM $0.12
- CARV $1.26
- 52 Week High
- AIM $0.62
- CARV $2.39
- Technical
- Relative Strength Index (RSI)
- AIM 36.62
- CARV 42.49
- Support Level
- AIM $0.12
- CARV $1.65
- Resistance Level
- AIM $0.21
- CARV $1.76
- Average True Range (ATR)
- AIM 0.02
- CARV 0.06
- MACD
- AIM -0.00
- CARV -0.00
- Stochastic Oscillator
- AIM 22.88
- CARV 25.00
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About CARV Carver Bancorp Inc.
Carver Bancorp Inc is a holding company and conducts its business as a unitary saving and loan holding firm and the business of the company consists of the operation of its subsidiary. The bank offers a wide range of financial solutions to meet customers' banking. It offers other consumer and commercial banking products and services, such as debit cards, online banking, online bill pay, and telephone banking. The company provides deposit products, such as demand, savings, and time deposits for consumers, businesses, and governmental and quasi-governmental agencies in its market area within New York City.